{"id":"https://openalex.org/W2224312414","doi":null,"title":"Dosificaci\u00f3n de Ribavirina y Peginterfer\u00f3n en pacientes con hepatitis C (genotipos 1 y 4)","display_name":"Dosificaci\u00f3n de Ribavirina y Peginterfer\u00f3n en pacientes con hepatitis C (genotipos 1 y 4)","publication_year":2012,"publication_date":"2012-01-01","ids":{"openalex":"https://openalex.org/W2224312414","mag":"2224312414"},"language":"es","primary_location":{"id":"mag:2224312414","doi":null,"is_oa":false,"landing_page_url":"https://dialnet.unirioja.es/servlet/articulo?codigo=4001077","pdf_url":null,"source":{"id":"https://openalex.org/S942739016","display_name":"Atenci\u00f3n farmac\u00e9utica","issn_l":"1139-7357","issn":["1139-7357"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Atenci\u00f3n farmac\u00e9utica","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Carmen Mart\u00edn","orcid":"https://orcid.org/0000-0002-2924-9390","observed_orcids":["https://orcid.org/0000-0002-2924-9390"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carmen Mart\u00edn","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-2924-9390","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052074993","display_name":"Jos\u00e9 Mar\u00eda Navarro-Jarabo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J.M. Navarro-Jarabo","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063412882","display_name":"B Tortajada Goitia","orcid":"https://orcid.org/0000-0003-2330-0914","observed_orcids":["https://orcid.org/0000-0003-2330-0914"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"B Tortajada Goitia","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2330-0914","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5110354678","display_name":"Vicente Faus Felipe","orcid":"https://orcid.org/0000-0002-3495-9952","observed_orcids":["https://orcid.org/0000-0002-3495-9952"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vicente Faus Felipe","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"14","issue":"2","first_page":"123","last_page":"128"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":0.8799999952316284},{"id":"https://openalex.org/keywords/pegylated-interferon","display_name":"pegylated interferon","score":0.949999988079071},{"id":"https://openalex.org/keywords/hepatitis-c","display_name":"hepatitis C","score":0.9290000200271606},{"id":"https://openalex.org/keywords/hcv-genotype-1","display_name":"HCV genotype 1","score":0.7559999823570251},{"id":"https://openalex.org/keywords/hcv-genotype-4","display_name":"HCV genotype 4","score":1.0},{"id":"https://openalex.org/keywords/dosage","display_name":"dosage","score":0.6579999923706055},{"id":"https://openalex.org/keywords/antiviral-therapy","display_name":"antiviral therapy","score":0.7519999742507935},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.36000001430511475}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8527357578277588}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2224312414","doi":null,"is_oa":false,"landing_page_url":"https://dialnet.unirioja.es/servlet/articulo?codigo=4001077","pdf_url":null,"source":{"id":"https://openalex.org/S942739016","display_name":"Atenci\u00f3n farmac\u00e9utica","issn_l":"1139-7357","issn":["1139-7357"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Atenci\u00f3n farmac\u00e9utica","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9476000070571899,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2030731913","https://openalex.org/W4250270258","https://openalex.org/W2399730696","https://openalex.org/W2051105678","https://openalex.org/W2017411948","https://openalex.org/W4229825472","https://openalex.org/W2323312091","https://openalex.org/W335513955","https://openalex.org/W7038539680","https://openalex.org/W2053036682"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}